Cytometry News and Research

RSS

BD announces acquisition of Sirigen

BD, a leading global medical technology company, announced today that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and can be applied to other technologies.

From BD (Becton, Dickinson and Company) 27 Aug 2012

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

Affymetrix second quarter total revenue increases to $66.4 million

Affymetrix, Inc., today reported its operating results for the second quarter of 2012. Total revenue for the quarter was $66.4 million, including approximately $1.4 million in revenue from eBioscience following the close of Affymetrix's acquisition of the company on June 25. This compares to total revenue of $64.7 million for the same period of 2011.

31 Jul 2012

Burn wound MSCs potential source for skin grafting

Study findings suggest that burn wound eschar-derived mesenchymal cells represent a population of multipotent stem cells, which could be a new resource for engineering approaches to heal burn wounds.

30 Jul 2012

NeoGenomics second quarter 2012 revenue increases 49% to $15.6 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the second quarter 2012.

19 Jul 2012

Methylation provides signal of unique mix of leukocytes

When a person is sick, there is a tell-tale sign in their blood: a different mix of the various types of immune cells called leukocytes. A group of scientists at several institutions including Brown University has discovered a way to determine that mix from the DNA in archival or fresh blood samples, potentially providing a practical new technology not only for medical research but also for clinical diagnosis and treatment monitoring of ailments including some cancers.

10 Jul 2012

New optical microscope identifies rare breast cancer cells

The ability to distinguish and isolate rare cells from among a large population of assorted cells has become increasingly important for the early detection of disease and for monitoring disease treatments.

7 Jul 2012

Affymetrix acquires eBioscience

Affymetrix Inc., today announced that the Company has completed its acquisition of eBioscience Holding Company, Inc., a privately-held company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics.

26 Jun 2012

DVS Sciences announces business agreement with Cytobank

DVS Sciences, Inc., a privately held innovator and manufacturer of novel CyTOF multi-parameter single-cell analyzers and reagents for biological research, today announced a business agreement with Cytobank, Inc., a privately held developer of cloud based scientific, informatics and software solutions for the flow cytometry market.

25 Jun 2012

Skin infections in AD patients linked to PMN impairment

Impairment of polymorphonuclear granulocytes among patients with atopic dermatitis may represent an additional cause of skin infections, suggest study findings.

22 Jun 2012

Study on identification of novel stem cell population in neuroblastoma to be presented at ANR conference

Dr. Eugene Kim, a pediatric surgeon with Texas Children's Cancer Center and assistant professor of surgery at Baylor College of Medicine (BCM), and Dr. Jason Shohet, chair of the Neuroblastoma Research Program at Texas Children's Cancer Center and associate professor in the Section of Hematology-Oncology at BCM, will speak at the Advances in Neuroblastoma Research (ANR) conference about the identification of a novel stem cell population in neuroblastoma.

19 Jun 2012

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed.

18 Jun 2012

Fate Therapeutics, BD Biosciences introduce first collaborative iPSC-related product

Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies.

From BD (Becton, Dickinson and Company) 11 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches a new subtype specific antibody as a marker for ankylosing spondylitis (AS): HLA-B*2705. The anti-HLA-B*2705 antibody, clone MARB4, has been validated for use in flow cytometry, tissue staining and immunoprecipitation.

30 May 2012

New optical microscope sees individual blood cells as they flow inside the body

Blood tests convey vital medical information, but the sight of a needle often causes anxiety and results take time. A new device developed by a team of researchers in Israel, however, can reveal much the same information as traditional blood test in real-time, simply by shining a light through the skin.

21 May 2012

High-throughput sequencing can detect early signs of leukemia relapse

A study led by researchers at Fred Hutchinson Cancer Research Center has found that a next-generation, high-speed DNA-decoding technology called high-throughput sequencing can detect the earliest signs of potential relapse in nearly twice the number of leukemia patients as compared to flow cytometry, the current gold standard for detecting minimal residual disease.

17 May 2012

Affymetrix to acquire eBioscience

Affymetrix, Inc., and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics, today announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience.

4 May 2012

Scientists use two different methods to visualize rare CTCs, double positive cells in mBC

New research from The Ohio State University utilizes two different methods to visualize circulating tumor cells (CTCs) as well as other unusual circulating cells with both epithelial and hematopoietic characteristics in metastatic breast cancer.

12 Apr 2012

New method for measurement of aggregated beta-amyloid in AD

An international team of researchers have developed a new method for measurement of aggregated beta-amyloid - a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer's disease. The new method might facilitate diagnosis and detection as well as development of drugs directed against aggregated beta-amyloid.

26 Mar 2012